Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02172651 · ClinicalTrials.gov registry record · Early Phase 1
Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases
A Early Phase 1 study of Stage, Colon Cancer and Stage I-III Colon Cancer, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT02172651: Recruiting Early Phase 1 study of Stage, Colon Cancer and Stage I-III Colon Cancer, sponsored by Dana-Farber Cancer Institute.
NCT02172651 is a Early Phase 1 study of Stage, Colon Cancer and Stage I-III Colon Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 80 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (51% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02172651, a Early Phase 1 study of Stage, Colon Cancer and Stage I-III Colon Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to learn more about the vitamin D receptor and its relationship to colon cancer. The Vitamin D receptor is found in colon cancer cells. When Vitamin D binds to the receptor in the cancer cells, it may stop cancer cells from growing abnormally and may cause cancer cell death. Vitamin D has been used in other research studies and information from those other research studies suggests that Vitamin D may help in the treatment of colon cancer. Participants will receive either high-dose vitamin D or standard-dose vitamin D. The study drug will be given 14-28 days prior to your surgery. The number of days will depend on when the surgery is scheduled.
Primary Outcome
For patients undergoing primary colon resection, the goal is to identify VDR binding sites in malignant and normal colonic tissue collected from colon cancer patients treated with high-dose vitamin D3 versus placebo. ChIP-Seq will be performed on frozen tumor tissue and adjacent normal colon tissue to determine VDR binding sites, which will be compared between the high-dose vitamin D and placebo arms, and between malignant tumor and normal colon tissue.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vitamin D3
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2014-07-14 |
| Est. Completion | 2026-06-30 |
| Phase | Early Phase 1 |
What NCT02172651 shows while recruiting
NCT02172651 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (51% higher).
The record links to 3 conditions, with Stage, Colon Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02172651 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02172651 about?
NCT02172651 is a clinical study titled "Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases". This study seeks to learn more about the vitamin D receptor and its relationship to colon cancer. The Vitamin D receptor is found in colon cancer cells. When Vitamin D binds to the receptor in the cancer cells, it may stop cancer cells from growing abnormally and may cause cancer cell death. Vitamin...
What is the current status of trial NCT02172651?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 80 participants. The study started on 2014-07-14. Estimated completion is 2026-06-30.
What conditions does trial NCT02172651 study?
This clinical trial studies the following conditions: Stage, Colon Cancer, Stage I-III Colon Cancer, Stage IV Colon Cancer With Resectable Liver Metastases.
What interventions are being tested in trial NCT02172651?
The interventions under investigation include: Placebo (DRUG), Vitamin D3 (DRUG).
Who is sponsoring clinical trial NCT02172651?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02172651 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02172651's enrollment target sits among peer trials
80 271st of 2000 higher than 1,704 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI